<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04102033</url>
  </required_header>
  <id_info>
    <org_study_id>Eltrombopag in ITP</org_study_id>
    <nct_id>NCT04102033</nct_id>
  </id_info>
  <brief_title>Eltrombopag in Chronic ITP</brief_title>
  <official_title>Efficacy of Eltrombopag in Chronic Immune Thrombocytopenia in Pediatrics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the efficacy of eltrombopag on the platelet count in pediatric
      patients with chronic immune thrombocytopenia.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2019</start_date>
  <completion_date type="Anticipated">January 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measuring the platelet count response to eltrombopag in pediatric chronic ITP</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Immune Thrombocytopenia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eltrombopag</intervention_name>
    <description>Thrombopietic agent approved for its efficacy in chronic immune thrombocytopenia in pediatric patients</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Pediatric patients with chronic ITP aged 1 to 17 years.

          2. Platelet count is less than 30×109 per liter.

          3. Patients neither have had spontaneous resolution of the thrombocytopenia nor responded
             to corticosteroids and/or IV immunoglobulin.

        Exclusion Criteria:

          1. Patients with clinical and/or laboratory evidence of hepatotoxicity/liver
             decompensation (Hepatotoxicity due to eltrombopag is defined as increased serum
             alanine aminotransferase ≥3 times the upper limit of normal (ULN), aspartate
             aminotransferase ≥3 ULN, alkaline phosphatase &gt;1.5 ULN, total bilirubin &gt;1.5 ULN)

          2. Patients with history of thrombotic/thromboembolic events.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gehad M. Abdelsalam, M.B.B.Ch</last_name>
    <phone>+201091294596</phone>
    <email>gehad011157@med.au.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mohammed M. Hamdy Ghazaly, M.D.</last_name>
    <phone>+201001296603</phone>
    <email>mohamed.ghazali1@med.au.edu.eg</email>
  </overall_contact_backup>
  <reference>
    <citation>Corman SL, Mohammad RA. Eltrombopag: a novel oral thrombopoietin receptor agonist. Ann Pharmacother. 2010 Jun;44(6):1072-9. doi: 10.1345/aph.1P042. Epub 2010 May 11. Review. Erratum in: Ann Pharmacother. 2010 Jul-Aug;44(7-8):1352-3.</citation>
    <PMID>20460556</PMID>
  </reference>
  <reference>
    <citation>Bussel JB, de Miguel PG, Despotovic JM, Grainger JD, Sevilla J, Blanchette VS, Krishnamurti L, Connor P, David M, Boayue KB, Matthews DC, Lambert MP, Marcello LM, Iyengar M, Chan GW, Chagin KD, Theodore D, Bailey CK, Bakshi KK. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. Lancet Haematol. 2015 Aug;2(8):e315-25. doi: 10.1016/S2352-3026(15)00114-3. Epub 2015 Jul 28. Erratum in: Lancet Haematol. 2015 Oct;2(10):e407.</citation>
    <PMID>26688484</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 23, 2019</study_first_submitted>
  <study_first_submitted_qc>September 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2019</study_first_posted>
  <last_update_submitted>September 23, 2019</last_update_submitted>
  <last_update_submitted_qc>September 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>GM Abdelsalam</investigator_full_name>
    <investigator_title>doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

